STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 249,503 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 249,503 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were acquired at an average price of $16.64 per share, for a total transaction of $4,151,729.92. Following the completion of the transaction, the insider now directly owns 11,953,198 shares in the company, valued at approximately $198,901,214.72. This trade represents a 2.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was acquired at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were acquired at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.46 per share, with a total value of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The shares were bought at an average cost of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The shares were bought at an average cost of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Stock Down 5.9 %

Shares of STAA traded down $1.03 during midday trading on Monday, reaching $16.47. The company had a trading volume of 1,350,529 shares, compared to its average volume of 1,112,576. The firm has a 50 day simple moving average of $21.55 and a 200-day simple moving average of $27.18. The stock has a market cap of $812.38 million, a PE ratio of -40.17 and a beta of 0.62. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of STAAR Surgical by 13.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock worth $2,684,000 after buying an additional 13,075 shares during the last quarter. Voloridge Investment Management LLC grew its position in STAAR Surgical by 9.4% in the fourth quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock worth $7,196,000 after acquiring an additional 25,350 shares during the period. Squarepoint Ops LLC increased its stake in STAAR Surgical by 81.3% during the fourth quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock worth $2,844,000 after acquiring an additional 52,488 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in STAAR Surgical in the fourth quarter valued at $502,000. Finally, Raiffeisen Bank International AG purchased a new stake in STAAR Surgical in the fourth quarter valued at $1,926,000. 96.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

STAA has been the topic of several research analyst reports. Stephens reiterated an “equal weight” rating and issued a $28.00 price objective on shares of STAAR Surgical in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Thursday. Mizuho downgraded STAAR Surgical from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. StockNews.com lowered STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus dropped their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and a consensus price target of $26.86.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.